drugset / Trial / NCT00516165

RAD001 in Advanced Hepatocellular Carcinoma

NCT00516165

NaSingle-groupOpen-labelTreatment

Summary

Laboratory studies have shown that RAD001 can prevent cells from multiplying. Consequently, the study drug is being tested in medical conditions in which excessive cell multiplication (as in cancer) needs to be stopped. The main purpose of this research study is to find the highest dose of RAD001 that can be given safely (without causing severe side effects) and to learn the effects (good or bad) RAD001 has on participants with liver cancer.

Timeline

Start
2007-08
Primary completion
2010-01
Completion
2011-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Everolimus Small molecule 10 mg Oral